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Prevention of mother-to-child transmis-
sion (MTCT) of HIV has been both a
great success and a continued challenge.
Today, in resource-rich countries, new
infant infections are a rare event. Howev-
er, nearly 400,000 infant HIV-1 infections
still occur each year in settings in which
highly active antiretroviral therapy
(HAART), elective caesarean sections,
and safe alternatives to breastfeeding are
not readily available. In these settings,
various short-course antiretroviral thera-
pies that include a single-dose of nevir-
apine (sdNVP) are used to prevent trans-
mission to infants [1]. The sdNVP
regimen effectively reduces MTCT by
close to 50% and is an inexpensive and
simple regimen, feasible for use in re-
source-limited settings [2,3]. However,
resistance to sdNVP arises commonly
and quickly and can adversely affect the
future treatment of NVP-exposed women
[4–6]. Ideal alternatives to the sdNVP
regimen would reduce the emergence of
resistance while preserving efficacy and
feasibility.
Alternatives to a Single Dose of
NVP to Reduce MTCT
A variety of alternative regimens have
efficacy in preventing MTCT in resource-
poor settings. These include daily zidovu-
dine (AZT) or zidovudine/lamivudine
(AZT/3TC) combinations, short-course
HAART, and infant-only prophylaxis
[7]. When considering which strategy is
most appropriate for use in resource-
limited settings, data on transmission rates
must be balanced with factors such as
resistance, safety, feasibility, and adher-
ence.
Despite the fact that it has been 10 years
since sdNVP was shown to be efficacious,
only about 10%–30% of pregnant women
who need sdNVP in resource-poor settings
have access to this affordable and simple
regimen [3,8]. This fact alone suggests that
more complex regimens, including short-
course HAART, may not be as rapidly
scaleable for preventing MTCT, despite
their superiority to sdNVP in preventing
transmission and resistance [9,10]. The
approach of infant-only treatment, while
avoiding resistance in the mother [11], is
unable to prevent the transmissions that
occur in utero or intrapartum, and does
not avoid resistance in infants that do
become infected. Thus, there is a compel-
ling need for a regimen that approaches
the simplicity of sdNVP while minimizing
resistance.
A Postpartum ‘‘Tail’’ of
Antiretrovirals Reduces
Resistance Following sdNVP
As described in a paper in this issue of
PLoS Medicine, Martinson et al. conducted
a randomized trial to determine whether
adding up to a week of twice-daily AZT/
3TC to sdNVP would reduce the risk of
resistance in mothers and infants [12].
The addition of AZT and 3TC (half-lives
1–2 h and 5–7 h, respectively) decreases
the amount of time that NVP (half-life
45 h) would be present alone, potentially
limiting selection pressure for resistance to
emerge. At 6 wk postpartum, drug resis-
tance in both mothers and infants was
reduced by over 80% in the sdNVP plus
AZT/3TC arms, compared to sdNVP
alone. In addition, at 2 wk postpartum,
viral loads were lower in the women on
combination treatment compared to those
who received sdNVP alone, which may
also have contributed to the observed
reduction in resistance. Not only did the
overall percentage of women and children
with resistance decrease, but following
sdNVP plus the ‘‘tail’’ of AZT/3TC,
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resistance appeared to fade more quickly.
These data have already had a global
impact. Preliminary analysis of the data
from this research study was presented at
the Conference on HIV Pathogenesis and
Treatment in 2005, and motivated a
change in the World Health Organization
(WHO) recommendations for preventing
MTCT in resource-limited settings [1,13].
Before these results were available, sdNVP
alone was the standard treatment recom-
mended by the WHO, despite the well-
known risk of resistance. It was simply the
most feasible regimen at the time. Today,
the current WHO recommended regimen
(AZT antepartum, sdNVP plus AZT/3TC
intrapartum, followed by AZT/3TC for
7 d postpartum) is based on the results
presented by Martinson, et al. as well as a
subsequent study that showed similar
findings [1,14]. More recent data suggest
that even simpler tail regimens may be
possible [15].
Some important questions remain. The
tail combination regimens provide a
shorter duration of single drug selection
pressure compared to sdNVP alone, and
result in a reduced prevalence of drug
resistance mutations that are detected by
the population-sequencing assays used.
However, the addition of a 1-wk tail may
not be enough to completely eliminate
NVP selection pressure, and it remains
possible that resistant virus still arises, but
only at low levels because of the more
limited period of selection. Whether low-
level resistance arises following these
regimens, and whether it has clinical
relevance, remains unclear and requires
testing with more sensitive drug resistance
assays [6].
Assuming that there is not a large
amount of lurking resistance that is below
the detection limit of the assays used in the
study presented, the approach of sdNVP
plus AZT/3TC to prevent MTCT may
strike the right balance of a feasible
regimen that minimizes resistance in
settings where HAART remains to be
implemented.
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